Alkermes, Inc.
News and overview for Alkermes, Inc.
Alkermes gains; Cerus, InterMune tumble - MarketWatch
MarketWatch | 5 days 20 hours 6 minutes ago
Shares of Alkermes /quotes/comstock/15*!alks/quotes/nls/alks (ALKS 8.91, +0.73, +8.92%) were up 10% at $9.02.
Drug stocks dip; Alkermes gains for second day - MarketWatch
MarketWatch | 5 days 21 hours 39 minutes ago
Drug stocks dip; Alkermes gains for second day
Drug stocks mixed; Alkermes slides - MarketWatch
MarketWatch | 16 days 20 hours 47 minutes ago
Shares of Alkermes /quotes/comstock/15*!alks/quotes/nls/alks (ALKS 7.74, -0.35, -4.33%) were down 4% at $7.77.
Drug stocks trend lower; Alkermes slides - MarketWatch
MarketWatch | 16 days 21 hours 44 minutes ago
Nasdaq Composite up 7.18 points to 2,112.50
Alkermes Reports Second Quarter Fiscal 2010 Financial Results [Press Release]
Business Wire | 17 days 15 hours 31 minutes ago
Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its second quarter of fiscal 2010, which ended on September 30, 2009.
Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence [Press Release]
Business Wire | 5 days 23 hours 1 minute ago
Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Alkermes takes 2Q loss, cuts full-year estimates
Richmond Times-Dispatch (Va.) | 17 days 11 hours 57 minutes ago
CAMBRIDGE, Mass. (AP) -- Biotech drug developer Alkermes Inc. said relocation charges and stock-based compensation costs pushed it to a loss in the fiscal second quarter.
Alkermes reports loss, and expects lower Risperdal Consta and Vivitrol revenue in fiscal 2010
Sun (Baltimore), The | 17 days 12 hours ago
Biotech drug developer Alkermes Inc. said relocation charges and stock-based compensation costs pushed it to a loss in the fiscal second quarter.
Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence [Press Release]
Business Wire | 6 days 23 hours 31 minutes ago
Alkermes, Inc. (NASDAQ: ALKS) today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulativ...
Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint
News-Medical.Net | 6 days 22 hours 17 minutes ago
Alkermes, Inc. (NASDAQ: ALKS) today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence
Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence
News-Medical.Net | 5 days 19 hours 59 minutes ago
Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Alkermes' Vivitrol succeeds in opiate study
Forbes | 6 days 20 hours 26 minutes ago
CAMBRIDGE, Mass. -- Alkermes Inc. said a late stage clinical trial shows its drug Vivitrol, which is used to help alcoholics quit drinking, also helped opioid addicts stay off drugs.
Alkermes says its anti-alcoholism drug met goal in late stage trial against opioid addiction
Orlando Sentinel (Fla.) | 6 days 20 hours 38 minutes ago
CAMBRIDGE, Mass. (AP) — Alkermes Inc. said a late stage clinical trial shows its drug Vivitrol, which is used to help alcoholics quit drinking, also helped opioid addicts stay off drugs.
Alkermes reports loss, and expects lower Risperdal Consta and Vivitrol revenue in fiscal 2010 -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 17 days 12 hours 23 minutes ago
CAMBRIDGE, Mass. (AP) — Biotech drug developer Alkermes Inc. said relocation charges and stock-based compensation costs pushed it to a loss in the fiscal second quarter.
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation [Press Release]
Business Wire | 27 days 1 minute ago
Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40...
Sign up for SNM SmartBrief
Company Overview
| Company: | Alkermes, Inc. |
|---|---|
| Industry: | Drug Delivery Systems |
| Website: | http://www.alkermes.com |
Alkermes, whose name is Arabic for "magic potion," is working some biotech alchemy. The firm uses its proprietary drug-delivery systems to make fragile biotech compounds that require less frequent dosing or provide more targeted delivery. Focusing on widespread diseases like diabetes, central nervous system disorders, and addiction, it has a couple of drugs on the market that use its injectable extended-release technology, which lets patients take a drug once or twice a month, rather than once or twice a day. One such drug is Risperdal Consta, a long-acting version of Janssen's schizophrenia medication Risperdal. Another is Vivitrol, a treatment for alcohol dependence that the company markets itself.
Key Numbers
| Sales in U.S. Dollars (mil.) | 326.8 (2009) |
|---|---|
| One-year % Growth in Sales | 35.8 (2009) |
| Net Income in U.S. Dollars (mil.) | 130.5 (2009) |
| One-year % Growth in Net Income | -21.8 (2009) |
| Number of Employees | 570 (2009) |
| One-year % Growth in Number of Employees | -6.6 (2009) |
| Fiscal Year-End | March |